You just read:

Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

News provided by

Regeneron Pharmaceuticals, Inc.

May 16, 2019, 07:00 ET